Moshe Oren
Weizmann Institute of Science
H-index: 144
Asia-Israel
Top articles of Moshe Oren
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
p53: A tale of complexity and context | Cell | Moshe Oren Carol Prives | 2024/3/28 |
ARTS and small-molecule ARTS mimetics upregulate p53 levels by promoting the degradation of XIAP | Oliver Hartmann Dorin Theodora Asiss Rabab Abbas Julia Kagan Hyoung-Tae Kim | 2023/12/1 | |
ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC | Cell Death & Disease | Kathrin Böpple Yaara Oren Whitney S Henry Meng Dong Sandra Weller | 2024/4/24 |
Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability | Molecular Systems Biology | YiQing Lü Tiffany Cho Saptaparna Mukherjee Carmen Florencia Suarez Nicolas S Gonzalez-Foutel | 2024/4/5 |
Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein | 2023/4/27 | ||
Deciphering the involvement of the Hippo pathway co-regulators, YAP/TAZ in invadopodia formation and matrix degradation | Cell death & disease | Jubina Balan Venghateri Bareket Dassa David Morgenstern Michal Shreberk-Shaked Moshe Oren | 2023/4/25 |
p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells | Proceedings of the National Academy of Sciences | Ori Hassin Miriam Sernik Adi Seligman Felix CE Vogel Max D Wellenstein | 2023/12/26 |
Drugging p53 in cancer: one protein, many targets | Ori Hassin Moshe Oren | 2023/2 | |
TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment | Molecular oncology | Anat Gershoni Ori Hassin Nishanth Belugali Nataraj Sivan Baruch Adi Avioz‐Seligman | 2023/12 |
Author Correction: Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis | Nature communications | Yael Aylon Noa Furth Giuseppe Mallel Gilgi Friedlander Nishanth Belugali Nataraj | 2023 |
Apoptotic cell death in disease—Current understanding of the NCCD 2023 | Ilio Vitale Federico Pietrocola Emma Guilbaud Stuart A Aaronson John M Abrams | 2023/5 | |
miR‐4734 conditionally suppresses ER stress‐associated proinflammatory responses | FEBS letters | Dan Michael Ester Feldmesser Chagay Gonen Noa Furth Alexander Maman | 2023/5 |
Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins | Proceedings of the National Academy of Sciences | Saptaparna Mukherjee Martino Maddalena YiQing Lü Sebastien Martinez Nishanth Belugali Nataraj | 2022/4/26 |
Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia | Haematologica | Amos Tuval Yardena Brilon Hadas Azogy Yoni Moskovitz Dena Leshkowitz | 2022/11/11 |
AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer | Cancer discovery | Ashish Noronha Nishanth Belugali Nataraj Joo Sang Lee Benny Zhitomirsky Yaara Oren | 2022/11/2 |
Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53 | 2022/8/11 | ||
Development of lead mutant-p53 reactivating peptides towards clinical application | Cancer Research | Perry Tal Moshe Oren Orna Palgi Varda Rotter Kwangil Jeong | 2022/6/15 |
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients | Nature communications | Ori Hassin Nishanth Belugali Nataraj Michal Shreberk-Shaked Yael Aylon Rona Yaeger | 2022/5/19 |
Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis | Nature communications | Yael Aylon Noa Furth Giuseppe Mallel Gilgi Friedlander Nishanth Belugali Nataraj | 2022/11/28 |
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment | Proceedings of the National Academy of Sciences | Martino Maddalena Giuseppe Mallel Nishanth Belugali Nataraj Michal Shreberk-Shaked Ori Hassin | 2021/6/8 |
Co-Authors
